Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextromethorphan + guaifenesin is a combination pharmaceutical developed by Strides Pharma Science. It is a small molecule drug administered orally, primarily indicated for the relief of cough and chest congestion. Dextromethorphan acts as an NMDA receptor antagonist and a Sigma-1 receptor agonist, providing antitussive (cough suppressant) effects. Guaifenesin functions as an expectorant, helping to thin and loosen mucus in the airways, making it easier to clear from the chest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + guaifenesin.